WASHINGTON – The FDA's call for more explicit labeling about birth defects for topiramate is not the news Vivus Inc. wanted to hear.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results